# A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes

> **NCT03952143** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 628 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** LY900014
- **DRUG:** Insulin Lispro
- **DRUG:** Insulin Glargine
- **DRUG:** Insulin Degludec

## Key facts

- **NCT ID:** NCT03952143
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-27
- **Primary completion:** 2021-01-20
- **Final completion:** 2021-01-20
- **Target enrollment:** 628 (ACTUAL)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03952143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03952143, "A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03952143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*